San Francisco, Calif. -- Results of a Phase 2a clinical trial evaluating the potential of NKTR-061 (inhaled amikacin) to treat hospital acquired gram-negative bacterial pneumonia will be presented at the American Thoracic Society (ATS) International Conference, May 18 23, 2007, in San Francisco.
WHO: Dr. Michael S. Niederman, MD, Chairman, Department of Medicine, Winthrop-University Hospital, Professor of Medicine; Vice Chairman, Department of Medicine, SUNY at Mineoloa.
Dr. Jean Chastre, Professor of Medicine, University of Paris.
WHAT: Four posters detailing the results of a Phase 2a clinical trial evaluating the pharmacokinetic, serum and tracheal aspirate concentration, safety and antibiotic reduction properties of NKTR-061.
Data will be presented and discussed at this ATS session to show a reduction in the use of IV antibiotics in mechanically ventilated patients during treatment of gram-negative pneumonia with NKTR-061. Further, the data indicate that the administration of NKTR-061 resulted in high tracheal aspirate concentrations and high epithelial lining fluid concentrations of amikacin in gram-negative pneumonia in intubated mechanically ventilated patients. Finally, data will be presented indicating that NKTR-061 achieves safe serum concentrations following multiple dosing in intubated mechanically ventilated patients with gram-negative pneumonia.
WHEN: Monday, May 21st, 2007, 8:15-11:00 am (PT)
WHERE: The American Thoracic Society (ATS) International Conference at the San Francisco Marriott Hotel.
NKTR-061 (inhaled amikacin) is being tested to evaluate the safety and tolerability of amikacin formulated for inhalation for the adjunctive treatment of gram-negative pneumonia in ventilated patients diagnosed with hospital or ventilator associated pneumonia. This new inhaled antibiotics product candidate leverages N
Contact: Tim Warner